Shares of Glaxo rose 0.5 percent to 1,432.50 pence as of 12:14 p.m. in London trading as sales for the quarter climbed 2 percent to 6.29 billion pounds, comparing with a 6.26 billion pound average estimate from analysts. Revenue from its blockbuster respiratory medicine Advair was 1.03 billion pounds, beating analysts’ estimate of 910.1 million pounds. GlaxoSmithKline Plc, the U.K.’s biggest drugmaker, posted fourth-quarter earnings that missed analysts’ estimates as sales of its pharmaceutical unit declined. Profit excluding certain costs dropped 23 percent to 1.36 billion pounds ($1.97 billion), the London-based company said in a statement on Wednesday. That missed the 1.47 billion pound average of nine analysts’ estimates compiled by Bloomberg. Core earnings per share of 18.1 pence matched the average of analyst estimates.